TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01763294

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nicolet Endeavor CR: 30min
Description: Transcranial direct current stimulation (tDCS) is a safe, non-invasive method that modulates cortical excitability. In direct current polarization, the cerebral cortex is stimulated through a weak constant electric current in a noninvasive and painless manner. This weak current induces focal changes of cortical excitability increase or decrease depending on the electrode polarity- that last beyond the period of stimulation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nicolet Endeavor CR: 60min
Description: Transcranial direct current stimulation (tDCS) is a safe, non-invasive method that modulates cortical excitability. In direct current polarization, the cerebral cortex is stimulated through a weak constant electric current in a noninvasive and painless manner. This weak current induces focal changes of cortical excitability increase or decrease depending on the electrode polarity- that last beyond the period of stimulation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nicolet Endeavor CR: 30min for 3 days
Description: Transcranial direct current stimulation (tDCS) is a safe, non-invasive method that modulates cortical excitability. In direct current polarization, the cerebral cortex is stimulated through a weak constant electric current in a noninvasive and painless manner. This weak current induces focal changes of cortical excitability increase or decrease depending on the electrode polarity- that last beyond the period of stimulation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nicolet Endeavor CR: 30min for 5 days
Description: Transcranial direct current stimulation (tDCS) is a safe, non-invasive method that modulates cortical excitability. In direct current polarization, the cerebral cortex is stimulated through a weak constant electric current in a noninvasive and painless manner. This weak current induces focal changes of cortical excitability increase or decrease depending on the electrode polarity- that last beyond the period of stimulation.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Nicolet Endeavor CR: Placebo
Description: The same procedures just that in this case the machine produces only a 60 second stimulus at the beginning so the patient can feel the initial electric stimulus.
Study: NCT01569386

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily low intensity physical activity by the half squat
Description: They take a meal three times daily. They are a time to do the manual work every day. They watch the TV for two hours every day. And they do a walk of 30 minutes every day. They do a specific exercise. They were trained to conduct 40kcal period(about 20 min.) for adding to the amount of energy consumption of low-intensity physical activity at baseline.Specific exercise that was done the half squat(max knee flexion 70 degree). This squat is carried out in two seconds round trip. This squat is carried out in two seconds round trip. They grab the edge of the table. They put half the weight of the lower limbs paralyzed side. This observer once a week, to record their behavior over 24 hours. Intervention period is up to a maximum of 12 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: stretch exercise and usual activity
Description: They take a meal three times daily.They are a time to do the manual work every day.They watch the TV for two hours every day.And they do a walk of 30 minutes every day.They do whole body stretch exercise for 20 minute in a day. An observer once a week, to record their behavior over 24 hours.Their behavior was used to calculate the amount of energy consumption.They are informed of the kcal a day from the viewer.
Study: NCT01329744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mecasermin
Description: a subcutaneous injection twice a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: Subcutaneous injection given twice per day of placebo compound, for 24 weeks
Study: NCT03569839

Intervention type: DRUG
Intervention: Propofol
Description: Patients undergoing surgery, TIVA (total intravenous anaesthesia)
Study: NCT01123824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLOPIDOGREL
Description: Pharmaceutical form: tablets~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLOPIDOGREL
Description: Pharmaceutical form: tablets~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Pharmaceutical form: matching tablets~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Pharmaceutical form: matching tablets~Route of administration: oral
Study: NCT03553082

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Fentanyl 2 µg/kg for induction of anesthesia and sevoflurane 2% for maintenance
Study: NCT03305328

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Alternating Current Stimulation
Description: Transcranial Alternating Current Stimulation passes a weak, 2 mA sinusoidal current through the scalp to the cortex at a specified frequency. Previous evidence suggests this exogenous sinusoidal stimulation interacts with the endogenous, cortical sinusoidal oscillatory activity, resulting in modulations of cortical oscillations. The intervention is non-invasive and virtually painless with no lasting adverse side-effects.
Study: NCT03553082

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol 5-6 mg/kg and fentanyl 2 µg/kg for induction of anesthesia and propofol 250-300 µg/kg/min for maintenance
Study: NCT03695965

Intervention type: PROCEDURE
Intervention: magnetic resonance imaging.
Description: 1.5 Tesla magnet system is going to be utilized for ankle imaging. A dedicated extremity surface coil (Foot/Ankle 16-Channel Coil; Siemens Medical Solution) is used to enhance spatial resolution.
Study: NCT04059107

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D Printed Myoelectric Prosthetic Device
Description: 3D Printed Myoelectric Prosthetic Device
Study: NCT02963701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Fixed dose combination

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Fixed dose combination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pseudoephedrine-HCl
Description: Fixed dose combination

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pseudoephedrine-HCl
Description: Fixed dose combination
Study: NCT01954316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CFI-400945
Description: Polo-like kinase 4 (PLK4) inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CFI-400945
Description: Polo-like kinase 4 (PLK4) inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CFI-400945
Description: Polo-like kinase 4 (PLK4) inhibitor
Study: NCT04119102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duobrii
Description: duobrii applied daily for 4 weeks followed by every other day for 4 weeks.
Study: NCT02998034

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Uncemented Furlong Hemiarthroplasty
Description: A furlong uncemeneted hyroxyapatite coated prosthesis.The hydroxyapatite stimulates bone ingrowth around the prosthesis and is this is thought to reduce loosening of the implant, residual pain and the long-term revision rate.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cemented tapered stem hemiarthroplasty
Description: A cemented double tapered stem hemiarthroplasty
Study: NCT03668834

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dermabrasion with NCES
Description: 1. The recipient site will be shaved, cleaned with betadine and surgical spirit and anaesthetized with mixture of 2% lignocaine and NS (1:1).~2. Dermabrasion will be done using Manekshaw's dermabrader until tiny pinpoint bleeding spots are seen and extended 5mm beyond margins to prevent halo phenomenon.~3. The denuded area will be washed with PBS and covered with a PBS moistened gauze piece.~4. With 18 G needle attached to tuberculine syringe, few small drops of non cultured epidermal cell suspension will be placed over the denuded surface and spread evenly.~5. Dressing is done in 4 layers in order-collagen(Neuskin F), bactigras, cutisoft(sterile gauze) and dynaplast (elastic plaster).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dermaroller with NCES
Description: 1. The recipient site will be shaved, cleaned with betadine and surgical spirit.~2. Microneedling will be done with a device containing 540 microneedles in 8 rows, each 0.25 mm in length. Microneedling will be extended 5 mm beyond margins to prevent halo phenomenon.~3. The roller will be passed repeatedly over the skin in a star-shaped way for about 10 minutes~4. The noncultured epidermal cell suspension will be carefully transferred to a tuberculin syringe.~5. NCES will be applied to the skin surface with a tuberculin syringe with an 18G needle and spread evenly after dermarolling treatment.~6. Dressing is done in 4 layers in order-collagen(Neuskin F), bactigras, cutisoft(sterile gauze) and dynaplast (elastic plaster).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Liquid nitrogen induced blister with NCES
Description: 1. The recipient site will be shaved, cleaned with betadine and surgical spirit and anaesthetized with mixture of 2% lignocaine and NS (1:1).~2. The site to be grafted is outlined with a surgical marking pen.~3. To induce blisters on the achromic areas, freezing with liquid nitrogen spray was performed during 10 to 20 seconds inside round circles previously drawn on the skin.~4. The patient is asked to visit 24 hours later.~5. The blister fluid is aspirated and NCES taken in tuberculin syringe with 18 G needle is injected into it such that the blister roof is preserved.~6. Dressing is done in 4 layers in order-collagen(Neuskin F), bactigras, cutisoft(sterile gauze) and dynaplast (elastic plaster).
Study: NCT00911573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tigecycline
Description: 50 mg IV every 12 hours up to 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clindamycin (or Vancomycin if needed)
Description: For clindamycin 10mg/kg (not to exceed 900mg) IV every 8 hours up to 14 days. For vancomycin 15mg/kg (not to exceed 2g/day and adjusted as needed for renal impairment) IV every 8 hours
Study: NCT04057885

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthosensor™ VERASENSE™ Knee System
Description: A group of patients will receive a total knee arthroplasty using the Orthosensor device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Orthosensor™ VERASENSE™ Knee System
Description: A group of patients will receive a total knee arthroplasty using the Orthosensor device
Study: NCT01508260

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Aquapheresis
Description: Participant connected to aquapheresis pump through an intravenous (IV) catheter placed in forearm. Average treatment is about 24 hours but can extend up to 7 days.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Aquapheresis
Description: Participant connected to aquapheresis pump through an intravenous (IV) catheter placed in forearm. Average treatment is about 24 hours but can extend up to 7 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide
Description: 20-40 mg by vein every 8 hours as indicated for optimal diuresis to achieve negative fluid balance or 0.5 to 5 mg per hour by continuous infusion.
Study: NCT00324233

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent catheter
Description: SpeediCath catherter (SC) for intermittent catherisation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Compact intermittent catheter
Description: SpeediCath Compact Male catheter (SCCM) is a compact intermittent catheter for males
Study: NCT03334383

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sponge
Description: Compressed cellulose sponge for use in laparoscopic surgery to retract the intestines from the surgical field.
Study: NCT03963102

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ameluz
Description: Leaving on the gel for 4 hours rather than the standard 3 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ameluz
Description: Leaving on the gel for 4 hours rather than the standard 3 hours.
Study: NCT01972789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Ranibizumab solution for injection is commercially supplied in two presentations: as a pre-filled syringe (containing 1.65 mg of ranibizumab in 0.165 mL solution) and as a vial (containing 2.3 mg of ranibizumab in 0.23 mL solution) corresponding to a recommended dose of 0.5 mg (0.05 mL) given as a single intravitreal injection. It will be prescribed and administered by the investigator or designee

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Ranibizumab solution for injection is commercially supplied in two presentations: as a pre-filled syringe (containing 1.65 mg of ranibizumab in 0.165 mL solution) and as a vial (containing 2.3 mg of ranibizumab in 0.23 mL solution) corresponding to a recommended dose of 0.5 mg (0.05 mL) given as a single intravitreal injection. It will be prescribed and administered by the investigator or designee
Study: NCT01493856

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cresto
Description: tablet, rosuvastatin 20mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olmetec
Description: tablet, olmesartan medoxomil(CS-866) 40mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWJ1276
Description: tablet, Rosuvastatin 20mg and olmesartan medoxomil 40mg
Study: NCT01853956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprazolam 0.25 mg
Description: Reference product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprazolam 0.25 mg
Description: Reference product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprazolam 0.25 mg
Description: Test product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprazolam 0.25 mg
Description: Test product
Study: NCT03984656

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine treatment
Description: The index marks the upper edge of the lower rib of the selected intercostal space to avoid the vasculonervous bundle sitting at the lower part of the overlying rib.Non-targeted subcutaneous infiltration is performed in the drainage area with 5 to 10 mL of Lidocaine 20 mg / mL non-adrenaline, plane by plane, with regular aspiration until air or fluid confirming effusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: serratus plane block treatment
Description: The Serratus plane block is located at the level of the 5th rib, on the midaxillary line, on the drainage side, ultrasound guided. The block is performed with a 70 mm needle in the ultrasound plane, and the needle is directed postero-inferior, after visualization of the structures from the surface to the depth: dorsal muscle~* anterior serratus large muscle (serratus anterior)~* intercostal muscle~* 4th and 5th ribs~* pleura A single injection of 30 mL of Ropivacaine 4.75 mg / mL is performed around the Serratus muscle.~An intravenous injection of 8 mg of Dexamethasone is added to prolong the duration of the block.
Study: NCT01685021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOR00208 (formerly Xmab5574)
Study: NCT03305328

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Alternating Current Stimulation
Description: Transcranial Alternating Current Stimulation passes a weak, 2 mA sinusoidal current through the scalp to the cortex at a specified frequency. Previous evidence suggests this exogenous sinusoidal stimulation interacts with the endogenous, cortical sinusoidal oscillatory activity, resulting in modulations of cortical oscillations. The intervention is non-invasive and virtually painless with no lasting adverse side-effects.
Study: NCT01531712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000mg/m2 / / 40mg/m2

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 50.4 Gy
Study: NCT06484361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA
Description: all patients will undergo PET/MRI with 68Ga-PSMA and 68Ga-RM2 prior to surgical intervention

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-RM2
Description: all patients will undergo PET/MRI with 68Ga-PSMA and 68Ga-RM2 prior to surgical intervention
Study: NCT01531712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tarceva
Description: 100mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 100mg/m2 (only in QT)
Study: NCT03822208

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AL003
Description: Single-doses of AL003 in dose-escalating cohorts~Multiple doses of AL003 in a single cohort
Study: NCT03442296

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Baltimore HEARS
Description: Tailored aural rehabilitation for participant and communication partner (if applicable)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Baltimore HEARS
Description: Tailored aural rehabilitation for participant and communication partner (if applicable)
Study: NCT03822208

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: Saline Solution will be administered as a single infusion for each dose escalation cohort in a ratio of 6 active and 2 placebo and as multiple infusions in the single cohort in a ratio of 10 active and 2 placebo
Study: NCT04734509

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silhouette breathing system
Description: The Silhouette is a single-use nasal mask and breathing circuit with lightweight tubing and an adhesive strip across the bridge of the nose to secure the mask in place and create a good seal around the patient's nose.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silhouette breathing system
Description: The Silhouette is a single-use nasal mask and breathing circuit with lightweight tubing and an adhesive strip across the bridge of the nose to secure the mask in place and create a good seal around the patient's nose.
Study: NCT03190655

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aluminaid
Description: Aluminaid wound dressings is a hydrogel based wound dressing that is integrated with aluminium

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hydrogel
Description: Hydrogel based wound dressing
Study: NCT01588691

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Eon-mini IPG (implantable pulse generator)
Description: programming parameters set at low frequency. Patients will receive this therapy dose for 3 weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Eon-mini IPG (implantable pulse generator)
Description: programming parameters set at high frequency. Patients will receive this therapy dose for 3 weeks.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Eon-mini IPG (implantable pulse generator)
Description: programming parameters set at lowest settings to deliver minimal power. Patients will receive this therapy dose for 3 weeks.
Study: NCT04022096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegoprazan 25mg QD
Description: Tegoprazan 25mg tablets will be orally administered, once daily, for up to 6 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole 15mg QD
Description: Lansoprazole 15mg capsules will be orally administered, once daily, for up to 6 months.
Study: NCT01997515

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Group K (ketamine) will receive 0.5mg /kg of ketamine bolus followed by an infusion of 0.5 mg/kg/hour of ketamine throughout the intraoperative period (Adjusted body weight).
Study: NCT01047709

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positional therapy including the use of a special pillow
Description: Avoidance of supine sleep via a special pillow and other measures.
Study: NCT00071500

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MedSignals™
Description: An electronic device that is used to improve medication compliance among HIV patients. It allows convenient storage and transport of antiretroviral medications and functions as an aid to compliance by incorporating reminding alarms at dosing times and usage reporting functions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MedSignals™
Description: An electronic device that is used to improve medication compliance among HIV patients. It allows convenient storage and transport of antiretroviral medications and functions as an aid to compliance by incorporating reminding alarms at dosing times and usage reporting functions.
Study: NCT01997515

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Group P (placebo) will receive the same amount of saline.
Study: NCT03369054

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Minority Stress Treatment
Description: The (MST) condition will include a psychoeducation session on minority stress for all participants during the initial assessment session prior to their first psychotherapy session. Prior to attending each of the 12 psychotherapy sessions during their electronic assessment (filling out the OQ-45 on Qualtrics on a computer provided by the study team), patients will be prompted to report up to three minority stress experiences over the previous week in the survey tool (which the therapists will not see). They will be prompted by their therapist to discuss these experiences within their psychotherapy sessions (for example, Would you like to discuss any of the minority stress experiences you've had over the week?).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As usual
Description: Treatment-as-usual (TAU) will occur as any usual 12-week treatment. The therapists will be encouraged to discuss any of the presenting concerns reported by patients and supervision will include usual care.
Study: NCT02393365

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaire
Description: All patients admitted to the one day clinic for surgery and gastroenterology will be asked, after signing an informed consent, to fill in a questionnaire about HCV risk factors.
Study: NCT01203228

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reduced Intensity Conditioning
Description: Busilvex®:~6.4 mg/kg IBW i. v. day -7: 0.8 mg/kg IBW x 4 (2 hour infusion every 6 hours) day -6: 0.8 mg/kg IBW x 4 (2 hour infusion every 6 hours)~or (if i.v.-application is not available)~Busulfan:~8.0 mg/kg BW p. o.: day -7: 4.0 mg/kg BW day -6: 4.0 mg/kg BW~plus:~Fludarabine:~5 x 30 mg/m² BS i. v.: day -7: 30 mg/m² BS day -6: 30 mg/m² BS day -5: 30 mg/m² BS day -4: 30 mg/m² BS day -3: 30 mg/m² BS